Supplementary Figure S6 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Q: What type of study is this?

This is a Phase 2 study (also classified as: RCT).

Chang Gon Kim; Min Hee Hong; Dahee Kim; Brian Hyohyoung Lee; Hyunwook Kim; Chan‐Young Ock; Geoffrey Kelly; Yoon Ji Bang; Gamin Kim; Jung Eun Lee; Chaeyeon Kim; Se‐Heon Kim; Hyun Jun Hong; Young Min Park; Nam Suk Sim; Heejung Park; Jin Woo Park; Chang Geol Lee; Kyung Hwan Kim; Goeun Park; Inkyung Jung; Dawoon Han; Jong Hoon Kim; Junha Cha; Insuk Lee; Mingu Kang; Heon Song; Chiyoon Oum; Seulki Kim; Sukjun Kim; Yoojoo Lim; Seunghee Kim‐Schulze; Miriam Mérad; Sun Och Yoon; Hyun Je Kim; Yoon Woo Koh; Hye Ryun Kim

doi:10.1158/1078-0432.29996658

Key Points

Pathologic response was compared between treatment groups, indicating significant outcomes.
Key evidence shows that the use of durvalumab plus tremelimumab may enhance neoadjuvant effects in certain patients.
The study employed an open-label randomized clinical trial design to assess treatment effectiveness over a neoadjuvant period.
Findings highlight the potential for improved response rates, emphasizing the need for further exploration in clinical settings.

Implication

Phase II trial evaluates pathologic and radiologic responses in head and neck squamous cell carcinoma, suggesting potential benefits of immunotherapy.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2025) studied this question.

synapsesocial.com/papers/68bb3a352b87ece8dc954cf3 https://doi.org/10.1158/1078-0432.29996658

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S6 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S6 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading